Citation Impact
Citing Papers
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Cancer statistics, 2022
2022 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Cancer Statistics, 2021
2021 Standout
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
2017
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
2007
Improving the efficacy of antibody-based cancer therapies
2001
Protein‐Based Nanomedicine Platforms for Drug Delivery
2009
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Combination cancer immunotherapy and new immunomodulatory targets
2015
The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
2010
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
2009
Prodrug Strategies in Anticancer Chemotherapy
2007
Linker Technologies for Antibody–Drug Conjugates
2013
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Site-specific antibody drug conjugates for cancer therapy
2013
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
2018
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer
2018
Fluorescent Nanorods and Nanospheres for Real‐Time In Vivo Probing of Nanoparticle Shape‐Dependent Tumor Penetration
2011 StandoutNobel
Immune checkpoint modulation: Rational design of combination strategies
2015
Current state of immunotherapy for non-small cell lung cancer
2007
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Radiotherapy: Changing the Game in Immunotherapy
2016
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
2017
Ligand-targeted therapeutics in anticancer therapy
2002
A Bioorthogonal Reaction of N‐Oxide and Boron Reagents
2015 StandoutNobel
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
2013
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
2004
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Tumor Angiogenesis
2008 Standout
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Arming antibodies: prospects and challenges for immunoconjugates
2005
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
2003
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Hepatocellular Carcinoma
2019 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
2009
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
2014
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
2013
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Plasmons in Strongly Coupled Metallic Nanostructures
2011 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
Cancer statistics, 2016
2016 Standout
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
Metal–Organic Frameworks in Biomedicine
2011 Standout
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
2009
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Diane Healey being referenced
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
2010
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
2009
137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors
2004
Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
2012
A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
2007
A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.
2001
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
1999
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
2010
Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors
2000
Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer
2008
OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
2017
Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC)
2004